Clinical Trials Logo

Clinical Trial Summary

Diabetes, beyond glycemic control, is a complex chronic disease that requires continuous medical care with multifactorial risk reduction strategies. It is necessary to reduce the likelihood of complications and additional problems that may develop in the long term. For this reason, guiding the patient to manage the disease process, equipping and supporting the patient with the necessary information is critical to prevent acute problems.

Exercise is the primary treatment method for diabetes patients. Exercise; It is the main treatment method used to increase aerobic capacity and improve respiratory capacity due to the positive effect it has on the body's structure and systems.


Clinical Trial Description

Firstly, patients were examined by the specialist doctor. If patients appropriate for this study according to inclusion and exclusion criteria, they were consulted to Cardiologist for stress ECG test and acceptation report to high or moderate-intensity aerobic training.

After baseline testing (including aerobic capacity and lung capacity), appropriate patients were randomized to HIIT or MICT groups involving sixteenth sessions of exercise performed over 6 weeks The HIIT exercise protocol involved 28 minutes of treadmill efforts. The patients performed the interval training for 4 minutes with 80%HRmax and active recovery period maintained for 3 minutes with 60% HRmax on the treadmill. This protocol repeated 4 times in a session. The MICT exercise protocol performed with %60 HRmax for 28 minutes similarly HIIT group. A 10-min warm-up and 10-min cool-down period were included for all groups. All groups reassessed after the 6. weeks (end of the exercise program) and 12. weeks (follow-up period).

Aerobic capacity assessed with an Incremental Shuttle Walk Test (ISWT). Clinicians need to 10 m field, audiotape recorder, chronometer, and two markers. This test consists of 12 levels, every level maintains1 minute and the walking speed is increased after every1 minute intervals. If the patients wanted to stop because of fell breathless or can't reach the end of the 10 m line' last 0.5 m in the time allowed, the test was stopped.Estimated VO2max was calculated a formula as "Estimated VO2max (ml/dk/kg)= 4.19 + (0.025 x ISWT distance)".

The patient's pulmonary functions assessed with a digital spirometer (Pony FX, COSMED Inc., Italy). Spirometer device measures FVC, FEV1, FEV1/FVC and PEF values. During the test, upper extremity was straight and patients sitting straight position on the chair with their vertical feet on the floor. The measurements were performed 3 times and the best score recorded with mean and standard deviation.

The measurements were coded into the analysis program and checked by a second researcher.

Post-hoc power analysis was done using aerobic capacity data, which is the main output of our study. The power of the study was determined as 94%.

Patients who had missing data, patients who did not complete the 6-weeks exercise program and 12. weeks follow-up period were excluded from the analysis. All analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 22. 0 for Windows. Data are expressed as mean ± standard deviation. The one-sample Kolmogorov-Smirnov test was performed to assess the distribution of data. Due to their distribution, numerical variables in different subjects were compared with the t-test or Mann-Whitney U test. Comparison of variables before and after the exercise program were compared by the paired t-test (parametric variable) or Wilcoxon test (non-parametric variable). Probability values were two-tailed, and a p-value of less than 0.05 was considered as significant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04330911
Study type Interventional
Source Marmara University
Contact
Status Completed
Phase N/A
Start date February 1, 2019
Completion date May 1, 2019

See also
  Status Clinical Trial Phase
Completed NCT02797392 - Feasibility of a Preventive Program Against Lifestyle Related Diseases N/A
Completed NCT01264523 - Nutritional Intervention With Moderately High-protein, Low-glycemic Load Products in Type-2 Diabetes Patients N/A
Completed NCT04105608 - GLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients. N/A
Completed NCT03624803 - DAPA - Egypt Study
Terminated NCT01787214 - Walnuts and Glucose Variability N/A
Completed NCT01715428 - Liraglutide and Cardio-Metabolic Risk Markers N/A
Completed NCT01884714 - Exploring the Molecular Basis to Healthy Obesity: The Diabetes Risk Assessment Study N/A
Completed NCT00567047 - Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment Phase 1
Completed NCT02191644 - Dietary Intervention Replacing Carbohydrate With Protein and Fat Has Greater Effect on Peripheral Blood Mononuclear Cell Metabolites Than on Plasma Metabolites in Patients With Prediabetes or Type-2 Diabetes Phase 2
Completed NCT01440660 - Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER) N/A
Completed NCT01343589 - Effects of Milk Derived From Mountain-pasture Grazing Cows on Risk Markers of the Metabolic Syndrome Compared to Conventional Danish Milk N/A
Completed NCT00651105 - Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects Phase 3
Completed NCT03269058 - Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes Phase 4
Completed NCT04952948 - Pilates Method on Functional Capacity and Blood Pressure of Elderly Women With Type 2 Diabetes N/A
Completed NCT00478127 - Hepatocyte Growth Factor and Cardiovascular Autonomic Function N/A